Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Measurable Residual Disease (MRD)”

235 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 235 results

Testing effectiveness (Phase 2)Ended earlyNCT03298412
What this trial is testing

Effect of Blinatumomab on Minimal Residual Disease (MRD) in Diffuse Large B-Cell Lymphoma (DLBCL) Subjects Post Autologous Hematopoietic Stem Cell Transplantation (aHSCT)

Who this might be right for
High-risk Diffuse Large B-cell Lymphoma
Amgen 10
Large-scale testing (Phase 3)Active Not RecruitingNCT04071457
What this trial is testing

S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

Who this might be right for
Multiple Myeloma
SWOG Cancer Research Network 1,100
Testing effectiveness (Phase 2)Active Not RecruitingNCT04521231
What this trial is testing

Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL

Who this might be right for
B Cell Precursor Acute Lymphoblastic Leukemia
Amgen 181
Not applicableNot Yet RecruitingNCT06854939
What this trial is testing

A Prospective Study Investigating the Relationship Between Minimal Residual Disease Detection, Monitoring Frequency, and Prognosis in Non-small Cell Lung Cancer Patients Eligible for Curative Treatment.

Who this might be right for
NSCLC, Stage I, II, III
National Cancer Center, Japan 350
Not applicableStudy completedNCT03521596
What this trial is testing

Non-invasive Diagnostics and Monitoring of MRD and Clonal Evolution in Waldenström's Macroglobulinemia and in IgM-MGUS

Who this might be right for
Waldenstrom Macroglobulinemia
Fondazione Italiana Linfomi - ETS 300
Not applicableLooking for participantsNCT06653062
What this trial is testing

Circulating Tumor Mitochondrial DNA (ct-mtDNA) As a Biomarker for Hepatocellular Carcinoma Recurrence Surveillance

Who this might be right for
Hepatocellular Carcinoma (HCC)
Tongji Hospital 50
Not applicableLooking for participantsNCT06463717
What this trial is testing

Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not

Who this might be right for
Multiple MyelomaMinimal Residual Disease
First Affiliated Hospital of Zhejiang University 210
Not applicableLooking for participantsNCT06230185
What this trial is testing

CtDNA Based MRD Testing for NAC Monitoring in TNBC

Who this might be right for
TNBC - Triple-Negative Breast CancerMinimal Residual Disease
Personalis Inc. 422
Not applicableLooking for participantsNCT06885476
What this trial is testing

Infusion of Alloreactive nk Cells for Mrd-positive Aml Patients

Who this might be right for
Acute Myeloid LeukemiaMinimal Residual DiseaseNatural Killer Cell
IRCCS Azienda Ospedaliero-Universitaria di Bologna 22
Testing effectiveness (Phase 2)Active Not RecruitingNCT04284787
What this trial is testing

BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAcute Myeloid Leukemia Post Cytotoxic Therapy+1 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Ended earlyNCT04526288
What this trial is testing

CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic Syndrome With Excess Blasts-2Myeloid Neoplasm
Fred Hutchinson Cancer Center 1
Not applicableLooking for participantsNCT06111105
What this trial is testing

GUIDE.MRD-01-CRC: Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Colorectal Cancer

Who this might be right for
Colorectal Cancer Stage IIILiver Metastasis Colon Cancer
Claus Lindbjerg Andersen 590
Large-scale testing (Phase 3)Looking for participantsNCT07441291
What this trial is testing

CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT

Who this might be right for
B ALLAllogenetic Hematopoietic Stem Cell TransplantationMRD-positive
Peking University People's Hospital 70
Large-scale testing (Phase 3)UnknownNCT03665480
What this trial is testing

The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML

Who this might be right for
Granulocyte Colony-stimulating FactorMinimal Residual DiseaseAcute Myeloid Leukemia
Nanfang Hospital, Southern Medical University 122
Not applicableLooking for participantsNCT05952661
What this trial is testing

Minimally Residual of Esophageal Cancer 001

Who this might be right for
Esophageal CarcinomaMinimal Residual Disease
Hebei Medical University Fourth Hospital 56
Not applicableLooking for participantsNCT06697483
What this trial is testing

Risk Stratification and MRD-driven Maintenance for MM After ASCT

Who this might be right for
Multiple Myeloma
Peking University People's Hospital 100
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07257380
What this trial is testing

Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric Cancer With Neoadjuvant Treatment: An Adaptive Trial (MRD-ATLAS)

Who this might be right for
Gastric / Gastroesophageal Junction Adenocarcinoma
Shanghai Zhongshan Hospital 90
Not applicableEnded earlyNCT04545333
What this trial is testing

The clonoSEQ® Watch Registry

Who this might be right for
Acute Lymphoblastic Leukemia, Adult B-CellChronic Lymphocytic LeukemiaMultiple Myeloma+1 more
Adaptive Biotechnologies 465
Not applicableLooking for participantsNCT06287814
What this trial is testing

French Assessment of MRD by Liquid Biopsies in Stage III CRC Patients (FRENCH.MRD.CRC)

Who this might be right for
Colorectal CancerStage III Colon CancerMinimal Residual Disease+1 more
University Hospital, Montpellier 70
Testing effectiveness (Phase 2)Looking for participantsNCT07392970
What this trial is testing

Motixafortide for MRD Sensitization in AML

Who this might be right for
Acute Myeloid LeukemiaMeasurable Residual Disease
Washington University School of Medicine 10
Next Page
60